[EDGC liquid biopsy ‘ONCOCATCH-CDx^TM logo / photo provided by EDGC]

Eone-Diagnomics Genome Center(EDGC) has established a bridgehead to preoccupy the European market for next-generation precision medical innovation technology liquid biopsy and secure personalized chemotheraphy big data. 

EDGC announced on 15^th that it has signed corporate marketing agreement with Molecular Health(MH), German biotechnology IT company, for liquid biopsy ‘ONCOCATCH-CDx^TM which is an early cancer diagnosis technology.

ONCOCATCH-CDx is leading-edge technology that analyzes cancer cell-derived ctDNA which is released from circulating tumor DNA (cell free DNA) in trace amount. This can be applied in all stage of cancer diagnosis and treatment based on early diagnosis of cancer, monitoring of cancer metastasis and recurrence and companion diagnostics for personalized anticancer therapy.

Especially, ONCOCATCH-CDx provide early diagnosis and tumor location of 10 major cancers such as colorectal cancer, lung cancer, breast cancer and stomach cancer through Methylation analysis with acquired somatic cell mutation that causes cancer and the specific pattern of tissue/cancer. Only Illumina(GRAIL) in the U.S and EDGC have such the highest level of technology development in the world.

For this reason, GenomeWeb, a global life science journal, reported that ONCOCATCH-CDx is the world’s best advanced technology for early cancer diagnosis.

EDGC liquid biopsy companion diagnosis service provides high-quality service for doctors and patients to make a decision about proper treatment by utilizing MH’s database platform ‘DATAOME’  which matches each patient’s personalized medicine prescription ingredients and quantity for about 28,000 genetic mutations

Based on this, not only corporate marketing of liquid biopsy ONCOCATCH-CDx, but also developing a program that will be helped medical team to prescribe personal anticancer drugs.  

“The co​operation between the two companies will greatly improve the diagnosis and personalized treatment of cancer in the precision medicine field.” said Stephan Hettich who is Senior Vice President of MH “We are very happy to enter and expand the Asian Market with EDGC.”

Jeong Yoo-seok, EDGC Global Business Department Team Leader, said that “When combining MH Guide, including 28.000 gene variant – drug relations, with EDGC’s companion diagnostics service ONCOCATCH-CDx is possible to prescribe personalized chemotheraphy for each patient. “We are looking forward to our partnership with Molecular Health to further establish our leading positions in the upcoming precision medicine market for liquid biopsy”, he adds.

In addition, MH is headquartered in Heidelberg, Germany, and provide service to government agency, hospital, pharmaceutical, and bio company in more than 30 countries including Europe and the United States.